筑波大学 医学医療系 つくば臨床医学研究開発機構(T-CReDO)臨床研究地域イノベーション学(JA寄附講座)
HOME 研究概要 研究業績
HOME > 研究業績


原著論文

松阪 諭

2018年

1. Nitta N, Sugimura T, Isozaki A, Mikami H, Hiraki K, Sakuma S, Iino T, Arai F, Endo T, Fujiwaki Y, Fukuzawa H, Hase M, Hayakawa T, Hiramatsu K, Hoshino Y, Inaba M, Ito T, Karakawa H, Kasai Y, Koizumi K, Lee S, Lei C, Li M, Maeno T, Matsusaka S, Murakami D, Nakagawa A, Oguchi Y, Oikawa M, Ota T, Shiba K, Shintaku H, Shirasaki Y, Suga K, Suzuki Y, Suzuki N, Tanaka Y, Tezuka H, Toyokawa C, Yalikun Y, Yamada M, Yamagishi M, Yamano T, Yasumoto A, Yatomi Y, Yazawa M, Di Carlo D, Hosokawa Y, Uemura S, Ozeki Y, Goda K. Intelligent Image-Activated Cell Sorting. Cell. 2018;175(1):266-276.

2. Berger MD, Stintzing S, Heinemann V, Cao S, Yang D, Sunakawa Y, Matsusaka S, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Hanna DL, Soni S, Puccini A, Zhang W, Cremolini C, Falcone A, Loupakis F, Lenz HJ. A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. Clin Cancer Res. 2018;24(4):784-793.

3. Hanna DL, Loupakis F, Yang D, Cremolini C, Schirripa M, Li M, Matsusaka S, Berger MD, Miyamoto Y, Zhang W, Ning Y, Antoniotti C, Salvatore L, Moran M, Zeger G, Astrow SH, Falcone A, Lenz HJ. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. Clin Colorectal Cancer. 2018 Sep;17(3):e471-e488. doi: 10.1016/j.clcc.2018.03.006. Epub 2018 Mar 14.

4. Matsusaka S, Wu AH, Cao S, Hanna DL, Chin K, Yang D, Zhang W, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Stremitzer S, Yamauchi S, Okazaki S, Berger MD, Parekh A, Miyamoto Y, Mizunuma N, Lenz HJ. Prognostic impact of FOXF1 polymorphisms in gastric cancer patients. Pharmacogenomics J. 2017;18(2):262-269.
5. Sebio A, Stintzing S, Heinemann V, Sunakawa Y, Zhang W, Ichikawa W, Tsuji A, Takahashi T, Parek A, Yang D, Cao S, Ning Y, Stremitzer S, Matsusaka S, Okazaki S, Barzi A, Berger MD, Lenz HJ. A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J. 2018;18(1):43-48.


2017年

1. Kimura Y, Fujii M, Masuishi T, Nishikawa K, Kunisaki C, Matsusaka S, Segawa Y, Nakamura M, Sasaki K, Nagao N, Hatachi Y, Yuasa Y, Asami S, Takeuchi M, Furukawa H, Nakajima T; JACCRO GC-06 Study Group. Correction to: Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC‑06). Gastric Cancer. 2017;21(3):421-427.

2. Berger MD, Stintzing S, Heinemann V, Yang D, Cao S, Sunakawa Y, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Soni S, Zhang W, Falcone A, Loupakis F, Lenz HJ. Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. Ann Oncol. 2017;28(11):2780-2785.

3. Okazaki S, Stintzing S, Sunakawa Y, Cao S, Zhang W, Yang D, Ning Y, Matsusaka S, Berger MD, Miyamoto Y, Suenaga M, Schirripa M, West JD, Gopez R, Akihito T, Ichikawa W, Heinemann V, DePaolo RW, Lenz HJ. Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. Int J Cancer. 2017;141(6):1222-1230.

4. Mishima Y, Matsusaka S (Mishima Y and Matsusaka contributed equally to this work), Chin K, Mikuniya M, Minowa S, Takayama T, Shibata H, Kuniyoshi R, Ogura M, Terui Y, Mizunuma N, Hatake K. Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients. Target Oncol. 2017;12(3):341-351.

5. Matsusaka S, Cao S, Hanna DL, Sunakawa Y, Ueno M, Mizunuma N, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Stremitzer S, Yamauchi S, Parekh A, Okazaki S, Berger MD, El-Khoueiry R, Mendez A, Ichikawa W, Loupakis F, Lenz HJ. CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy. Pharmacogenomics J. 2017;17(6):543-550.

6. Berger MD, Yamauchi S, Cao S, Hanna DL, Sunakawa Y, Schirripa M, Matsusaka S, Yang D, Groshen S, Zhang W, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Lonardi S, Cremolini C, Falcone A, Heinemann V, Loupakis F, Stintzing S, Lenz HJ. Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. Eur J Cancer. 2017; 77:13-20.

7. Sunakawa Y, Cao S, Volz NB, Berger MD, Yang D, Parekh A, Zhang W, Matsusaka S, Ning Y, Stremitzer S, Stintzing S, Sebio A, Okazaki S, Wakatsuki T, Azuma M, Watanabe M, Koizumi W, Wu AH, Lenz HJ. Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer. Pharmacogenomics J. 2017;17(6):528-534.

8. Hosoya K, Matsusaka S (Hosoya K and Matsusaka contributed equally to this work), Kashiwada T, Suzuki K, Ureshino N, Sato A, Miki Y, Kitera K, Hirai M, Hatake K, Kimura S, Sueoka-Aragane N. Detection of KRAS Mutations in Plasma DNA Using a fully Automated Rapid Detection System in Colorectal Cancer Patients. Pathol Oncol Res. 2017;23(4):737-744.

9. Nakayama N, Ishido K, Chin K, Nishimura K, Azuma M, Matsusaka S, Inokuchi Y, Tanabe S, Kumekawa Y, Koizumi W. A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer. Gastric Cancer. 2017;20(2):350-357.

10. Stremitzer S, Berghoff AS, Volz NB, Zhang W, Yang D, Stintzing S, Ning Y, Sunakawa Y, Yamauchi S, Sebio A, Matsusaka S, Okazaki S, Hanna D, Parekh A, Mendez A, Berger MD, El-Khoueiry R, Birner P, Preusser M, Lenz HJ. Genetic variants associated with colorectal brain metastases susceptibility and survival. Pharmacogenomics J. 2017;17(1):29-35.

11. Sunakawa Y, Cao S, Berger MD, Matsusaka S, Yang D, Zhang W, Ning Y, Parekh A, Stremitzer S, Mendez A, Okazaki S, Wakatsuki T, Azuma M, Shimada K, Watanabe M, Koizumi W, Wu AH, Lenz HJ. Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer. Pharmacogenomics J. 2017;17(1):36-41.


2016年

1. Matsusaka S, Nashimoto A, Nishikawa K, Miki A, Miwa H, Yamaguchi K, Yoshikawa T, Ochiai A, Morita S, Sano T, Kodera Y, Kakeji Y, Sakamoto J, Saji S, Yoshida K. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101). Gastric Cancer. 2016;19(3):839-51.

2. Matsusaka S, Yoshida K. Letter in response to "Our HER2 is same as yours". Transl Gastroenterol Hepatol. 2016;1:18.

3. Stremitzer S, Zhang W, Yang D, Ning Y, Sunakawa Y, Matsusaka S, Parekh A, Okazaki S, Hanna D, Astrow SH, Moran M, Hernandez J, Stephens C, Scherer SJ, Stift J, Wrba F, Gruenberger T, Lenz HJ. Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection. Mol Cancer Ther. 2016;15(11):2814-2821.

4. Berger MD, Yang D, Sunakawa Y, Zhang W, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Lenz AM, Bohanes P, Barzi A, Figueiredo JC, Hanna DL, Lenz HJ. Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012. Oncotarget. 2016;7(33):53668-53678.

5. Okazaki S, Loupakis F, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Stremitzer S, Matsusaka S, Berger MD, Parekh A, West JD, Miyamoto Y, Suenaga M, Schirripa M, Cremolini C, Falcone A, Heinemann V, DePaolo RW, Lenz HJ. Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. Mol Cancer Ther. 2016;15(7):1740-5.

6. Suenaga M, Mashima T, Kawata N, Wakatsuki T, Horiike Y, Matsusaka S, Dan S, Shinozaki E, Seimiya H, Mizunuma N, Yamaguchi K, Yamaguchi T. Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer. Oncotarget. 2016;7(23):34811-23.

7. Matsusaka S, Kobunai T, Yamamoto N, Chin K, Ogura M, Tanaka G, Matsuoka K, Ishikawa Y, Mizunuma N, Yamaguchi T. Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy. Genes Cancer. 2016;7(1-2):27-35.

8. Osumi H, Shinozaki E, Suenaga M, Matsusaka S, Konishi T, Akiyoshi T, Fujimoto Y, Nagayama S, Fukunaga Y, Ueno M, Mise Y, Ishizawa T, Inoue Y, Takahashi Y, Saiura A, Uehara H, Mun M, Okumura S, Mizunuma N, Miki Y, Yamaguchi T. RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy. Int J Cancer. 2016;139(4):803-11.

9. Matsusaka S, Zhang W, Cao S, Hanna DL, Sunakawa Y, Sebio A, Ueno M, Yang D, Ning Y, Parekh A, Okazaki S, Berger MD, Ichikawa W, Mizunuma N, Lenz HJ. TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy. Mol Cancer Ther. 2016;15(6):1405-11.

10. Matsusaka S, Hanna DL, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Okazaki S, Berger MD, Miyamato Y, Parekh A, Stintzing S, Loupakis F, Lenz HJ. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. Clin Cancer Res. 2016;22(13):3218-26.

11. Osumi H, Yoshio T, Chin K, Ogura M, Kumekawa Y, Suenaga M, Matsusaka S, Shinozaki E, Miyamoto Y, Morishige K, Ishiyama A, Hirasawa T, Tsuchida T, Yamamoto Y, Fujisaki J, Igarashi M, Mizunuma N. Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer. Gastric Cancer. 2016;19(2):625-30.

12. Sebio A, Matsusaka S, Zhang W, Yang D, Ning Y, Stremitzer S, Stintzing S, Sunakawa Y, Yamauchi S, Fujimoto Y, Ueno M, Lenz HJ. Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer. Pharmacogenomics J. 2016;16(4):312-9.


2015年

1. Osumi H, Matsusaka S, Wakatsuki T, Suenaga M, Shinozaki E, Mizunuma N. Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients. Mol Clin Oncol. 2015;3(6):1295-1300.

2. Sato Y, Matsusaka S, Suenaga M, Shinozaki E, Mizunuma N. Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients. Onco Targets Ther. 2015;8:3329-36.

3. Osumi H, Shinozaki E, Osako M, Kawazoe Y, Oba M, Misaka T, Goto T, Kamo H, Suenaga M, Kumekawa Y, Ogura M, Ozaka M, Matsusaka S, Chin K, Hatake K, Mizunuma N. Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival. Mol Clin Oncol. 2015;3(5):1053-1057.

4. Osumi H, Shinozaki E, Suenaga M, Kumekawa Y, Ogura M, Ozaka M, Matsusaka S, Chin K, Yamamoto N, Mizunuma N. Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy? BMC Cancer. 2015;15:760.

5. Sunakawa Y, Stintzing S, Cao S, Heinemann V, Cremolini C, Falcone A, Yang D, Zhang W, Ning Y, Stremitzer S, Matsusaka S, Yamauchi S, Parekh A, Okazaki S, Berger MD, Graver S, Mendez A, Scherer SJ, Loupakis F, Lenz HJ. Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials. Ann Oncol. 2015;26(12):2450-6.

6. Matsusaka S, Ishihara S, Kondo K, Horie H, Uehara K, Oguchi M, Murofushi K, Ueno M, Mizunuma N, Shimbo T, Kato D, Okuda J, Hashiguchi Y, Nakazawa M, Sunami E, Kawai K, Yamashita H, Okada T, Ishikawa Y, Nakajima T, Watanabe T. A multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (SHOGUN trial). Radiother Oncol. 2015;116(2):209-13.

7. Osumi H, Matsusaka S, Suenaga M, Shinozaki E, Mizunuma N. Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab. Onco Targets Ther. 2015;8:2005-13.

8. Ning Y, Hanna DL, Zhang W, Mendez A, Yang D, El-Khoueiry R, Matsusaka S, Sunakawa Y, Stremitzer S, Parekh A, Okazaki S, Berger MD, Barzi A, Lenz HJ. Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. Mol Cancer Ther. 2015;14(10):2401-8.

9. Stintzing S, Zhang W, Heinemann V, Neureiter D, Kemmerling R, Kirchner T, Jung A, Folwaczny M, Yang D, Ning Y, Sebio A, Stremitzer S, Sunakawa Y, Matsusaka S, Yamauchi S, Loupakis F, Cremolini C, Falcone A, Lenz HJ. Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. Mol Cancer Ther. 2015;14(10):2374-81.

10. Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Yamaguchi T. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des Devel Ther. 2015;9:3099-108.

11. Suenaga M, Fujimoto Y, Matsusaka S, Shinozaki E, Akiyoshi T, Nagayama S, Fukunaga Y, Oya M, Ueno M, Mizunuma N, Yamaguchi T. Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01). Onco Targets Ther. 2015;8:1111-8.

12. Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sunakawa Y, Sebio A, Yamauchi S, Matsusaka S, Parekh A, Barzi A, El-Khoueiry R, Stift J, Wrba F, Gruenberger T, Lenz HJ. Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases. Ann Oncol. 2015;26(8):1728-33.

13. Suzuki S, Matsusaka S, Hirai M, Shibata H, Takagi K, Mizunuma N, Hatake K. A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction. Int J Oncol. 2015;47(1):97-105.

14. Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Chin K, Yamaguchi T. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer. Drug Des Devel Ther. 2015;9:1653-62.

15. Ohhara Y, Suenaga M, Matsusaka S, Shinozaki E, Mizunuma N, Yamaguchi T. Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer. Onco Targets Ther. 2015;8:529-37.

16. Stremitzer S, Sunakawa Y, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Yamauchi S, Matsusaka S, El-Khoueiry R, Stift J, Wrba F, Gruenberger T, Lenz HJ. Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases. Pharmacogenomics J. 2015;15(6):521-9.

17. Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Yamauchi S, Matsusaka S, El-Khoueiry R, Stift J, Wrba F, Gruenberger T, Lenz HJ. Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases. Cancer. 2015;121(11):1898-905.

18. Suenaga M, Mizunuma N, Shinozaki E, Matsusaka S, Ozaka M, Ogura M, Chin K, Yamaguchi T. Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab. Onco Targets Ther. 2015;8:243-9.

19. Ishihara S, Matsusaka S, Kondo K, Horie H, Uehara K, Oguchi M, Murofushi K, Ueno M, Mizunuma N, Shinbo T, Kato D, Okuda J, Hashiguchi Y, Nakazawa M, Sunami E, Kawai K, Yamashita H, Okada T, Ishikawa Y, Nakajima T, Watanabe T. A phase I dose escalation study of oxaliplatin plus oral S-1 and pelvic radiation in patients with locally advanced rectal cancer (SHOGUN trial). Radiat Oncol. 2015;10:24.

20. Sunakawa Y, Stremitzer S, Cao S, Zhang W, Yang D, Wakatsuki T, Ning Y, Yamauchi S, Stintzing S, Sebio A, El-Khoueiry R, Matsusaka S, Parekh A, Barzi A, Azuma M, Watanabe M, Koizumi W, Lenz HJ. Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer. Ann Oncol. 2015;26(2):332-9.

21. Sebio A, Gerger A, Matsusaka S, Yang D, Zhang W, Stremitzer S, Stintzing S, Sunakawa Y, Yamauchi S, Ning Y, Fujimoto Y, Ueno M, Lenz HJ. Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer. Pharmacogenet Genomics. 2015;25(1):30-7.


2014年

1. Matsusaka S, Kozuka M, Takagi H, Ito H, Minowa S, Hirai M, Hatake K. A novel detection strategy for living circulating tumor cells using 5-aminolevulinic acid. Cancer Lett. 2014;355(1):113-20.

2. Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ueno M, Yamaguchi T. Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer. Asia Pac J Clin Oncol. 2014;10(4):322-9.

3. Wakatsuki T, Stintzing S, Zhang W, Yang D, Azuma M, Ning Y, Yamauchi S, Matsusaka S, Volz NB, Sunakawa Y, Koizumi W, Watanabe M, Barzi A, El Khoueiry AB, Shah MA, Lenz HJ. Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent. Pharmacogenet Genomics. 2014;24(11):539-47.





町野 毅

2018年

1. Yamasaki H, Yamagami F, Machino T, Kuroki K, Sekiguchi Y, Aonuma K, Nogami A. Perforation of the Left Atrial Appendage Caused by Inadvertent Deployment of a Soft J-Tipped Guidewire During Radiofrequency Hot-Balloon Ablation. Circ J. 2018;82(5):1476-1477.


2017年

2. Machino T. Thyroid hormones and arrhythmia (Focused review on atrial fibrillation). Journal of the Japan Thyroid Association. 2017;8(2):14-23.

3. Kuroki K, Nogami A, Yoshida K, Goya M, Fukunaga M, Kaitani K, Onishi N, Mine T, Koyama T, Igawa M, Machino T, Yamasaki H, Xu D, Igarashi M, Murakoshi N, Sekiguchi Y, Aonuma K. Efficacy of Intensive Radiofrequency Energy Delivery to the Localized Dense Scar Area in Post-Infarction Ventricular Tachycardia Ablation - A Comparative Study With Standard Strategy Targeting the Infarcted Border Zone. Circ J. 2017;81(11):1603-1610.

4. Yui Y, Sekiguchi Y, Nogami A, Yamasaki H, Machino T, Kuroki K, Igarashi M, Aonuma K. Electrophysiological Characteristics and Radiofrequency Catheter Ablation Treatment of Idiopathic Ventricular Arrhythmias Successfully Ablated From the Ostium of the Coronary Sinus. Circ J. 2017;81(12):1807-1815.

5. Igarashi M, Tada H, Yamasaki H, Kuroki K, Ishizu T, Seo Y, Machino T, Murakoshi N, Sekiguchi Y, Noguchi Y, Nogami A, Aonuma K. Fragmented QRS Is a Novel Risk Factor for Ventricular Arrhythmic Events After Receiving Cardiac Resynchronization Therapy in Nonischemic Cardiomyopathy. J Cardiovasc Electrophysiol. 2017;28(3):327-335.


2016年

6. Naruse Y, Nogami A, Shinoda Y, Hanaki Y, Shirai Y, Kowase S, Kurosaki K, Machino T, Kuroki K, Yamasaki H, Igarashi M, Sekiguchi Y, Aonuma K. J Waves Are Associated With the Increased Occurrence of Life-Threatening Ventricular Tachyarrhythmia in Patients With Nonischemic Cardiomyopathy. J Cardiovasc Electrophysiol. 2016;27(12):1448-1453.

7. Seo Y, Ishizu T, Machino-Ohtsuka T, Yamamoto M, Machino T, Kuroki K, Yamasaki H, Sekiguchi Y, Nogami A, Aonuma K. Incremental Value of Speckle Tracking Echocardiography to Predict Cardiac Resynchronization Therapy (CRT) Responders. Journal of the American Heart Association. 2016;5(10):e003882.


2015年

8. Igarashi M, Nogami A, Sekiguchi Y, Kuroki K, Yamasaki H, Machino T, Yui Y, Ogawa K, Talib AK, Murakoshi N, Kuga K, Aonuma K. The QRS morphology pattern in V5R is a novel and simple parameter for differentiating the origin of idiopathic outflow tract ventricular arrhythmias. Europace. 2015;17(7):1107-1116.

9. Machino T, Sekiguchi Y. Positive Pocket Cultures From Cardiac Implantable Electrophysiological Devices Without Infection - Contamination or Colonization? Circ J. 2015;79(8):1680-1681.

10. Kuroki K, Tada H, Kunugida F, Sekiguchi Y, Machino T, Yamasaki H, Igarashi M, Aonuma K. Hybrid epicardial and endocardial ablation of a persistent atrial tachycardia arising from the marshall bundle: the importance of a detailed analysis of the local potentials. Heart Vessels. 2015;30(3):416-419.


2014年

11. Machino T, Murakoshi N, Sato A, Xu D, Hoshi T, Kimura T, Aonuma K. Anti-hypertensive effect of radiofrequency renal denervation in spontaneously hypertensive rats. Life Sci. 2014;110(2):86-92.

12. Naruse Y, Sekiguchi Y, Nogami A, Okada H, Yamauchi Y, Machino T, Kuroki K, Ito Y, Yamasaki H, Igarashi M, Tada H, Nitta J, Xu D, Sato A, Aonuma K. Systematic treatment approach to ventricular tachycardia in cardiac sarcoidosis. Circ Arrhythm Electrophysiol. 2014;7(3):407-413.

13. Machino T, Tada H, Sekiguchi Y, Naruse Y, Kuroki K, Yamasaki H, Igarashi M, Yoshida K, Nogami A, Aonuma K. Counterclockwise Heart Rotation Affects Variation in Successful Ablation Line Position in Common Atrial Flutter. Circ J. 2014;78(4):859-864.





山田 武史

2018年

1. Yukako Hamano, Toshikazu Moriwaki, Keii To, Takahisa Watahiki, Takeshi Yamada, Shingo Sakashita, Ichinosuke Hyodo. A neuroendocrine tumor of unknown primary origin that responded to treatment based on tumor grade progression: a case report. Internal Medicine 2018, accepted.

2. Yamada T, Hamano Y, Hasegawa N, Yokoyama KK, Hyodo I, Abei M. Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers. Curr Cancer Drug Targets. Vol.18, 188-201, 2018


2016年

3. 百賢二,山田武史,鶴島英夫,荒川義弘 一般市民を対象とした企業主導治験に伴う遺伝子解析研究に対する意識調査 医薬品情報学 第19巻、59-63頁、2017

4. 安部井誠人,山田武史,長谷川直之,兵頭一之介,山口巌 血液透析療法中慢性腎不全合併C型肝炎ウイルス感染症に対するOmbitasvir/Paritaprevir/Ritonavir療法の効果 肝臓 第57巻、565-567頁、2016

5. Moriwaki T, Yamamoto Y, Gosho M, Kobayashi M, Sugaya A, Yamada T, Endo S, Hyodo I. Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomized trials of first-line chemotherapy. Br J Cancer. Vol.114, 881-888, 2016

6. Yamada T, Yamamoto Y, Moriwaki T and Hyodo I. Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer? J Gastroenterol Vol.51, 506-507, 2016


2015年

7. Yamada T, Abei M, Danjoh I, Shirota R, Taro Y, Hyodo I, Nakamura Y. Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib. BMC Cancer Vol.15, 260 (Web掲載14ページ), 2015

8. 菅谷明徳、森脇俊和、田島大樹、今西真実子、浜野由花子、小林真理子、圷大輔、小林克誠、越智大介、山田武史、山本祥之、遠藤慎治、鈴木英雄、兵頭一之介 KRAS遺伝子野生型治癒切除不能大腸癌に対する2次治療以降の抗EGFR抗体薬単剤の検討 癌と化学療法 第42巻、189-193頁、2015


2014年

9. Moriwaki T, Ishige K, Araki M, Yoshida S, Nishi M, Sato M, Yamada T, Yamamoto Y, Ozeki M, Ishida H, Yamaguchi T, Matsuda K, Murashita T, Abei M, Hyodo I.  Glasgow Prognostic Score predicts poor prognosis among advanced biliary tract cancer patients with good performance status.  Med Oncol. Vol.31, 287(Web掲載6ページ), 2014

10. Moriwaki T, Kajiwara T, Matsumoto T, Suzuki H, Hiroshima Y, Matsuda K, Hirai S, Yamamoto Y, Yamada T, Sugaya A, Kobayashi M, Endo S, Ishige K, Nishina T, Hyodo I. Survival analysis of platinum-refractory patients with advanced esophageal cancer treated with docetaxel or best supportive care alone: a retrospective study. Diseases of the Esophagus Vol.27, 737-743, 2014

11. Endo S, Saito R, Ochi D, Yamada T, Hirose M, Hiroshima Y, Yamamoto Y, Ueno T, Hasegawa N, Moriwaki T, Narasaka T, Kaneko T, Fukuda K, Suzuki H, Mizokami Y, Hyodo I.  Effectiveness of an Endoscopic Biopsy Procedure Using EUS-FNA and EMR-C for Diagnosing Adenocarcinoma Arising from Ectopic Pancreas: Two Case Reports and a Literature Review.  Intern Med. Vol.53, 1055-1062, 2014

12. Yamada T, Sugiyama H, Ochi D, Akutsu D, Suzuki H, Narasaka T, Moriwaki T, Endo S, Kaneko T, Satomi K, Ikezawa K, Mizokami Y, Hyodo I. Risk factors for submucosal and lymphovascular invasion in gastric cancer looking indicative for endoscopic submucosal dissection. Gastric Cancer. Vol.17, 692-696, 2014

13. 小林真理子、森脇俊和、越智大介、斉藤梨絵、小林克誠、菅谷明徳、圷大輔、浜野由花子、今西真実子、山本祥之、山田武史、中野雅之、菅野雅人、原健、兵頭一之介:シスプラチン(CDDP)+ペメトレキセド(PEM)療法が奏功した上皮型悪性腹膜中皮腫の1例、癌と化学療法 第41巻、361-364頁、2014

14. Yamamoto Y, Yamada T, Akutsu D, Sugaya A, Murashita T, Matsuda K, Yamamoto Y, Kusakabe R, Kaneko T, Suzuki H, Hyodo I, Sato T, Takayashiki N, Murakoshi N, Hara K, Mizokami Y. Collagenous sprue diagnosed by double balloon endoscopy. Dig Endosc. Vol.26, 108-112, 2014



筑波大学 筑波大学附属病院 筑波大学医学医療系
筑波大学つくば臨床医学研究開発機構 Tsukuba Clinical Research & Development Organization 茨城県厚生農業協同組合連合会 革新的研究開発推進プログラム(impact)


筑波大学 医学医療系 つくば臨床医学研究開発機構(T-CReDO)臨床研究地域イノベーション学(JA寄附講座)
医学医療系
臨床研究地域イノベーション学(JA茨城県厚生連寄附講座)
つくば臨床医学研究開発機構(T-CReDO)
〒305-8575
茨城県つくば市天王台1-1-1
℡/Fax 029-853-3076




HOME研究概要研究業績

Copyright© 2018 筑波大学 医学医療系 つくば臨床医学研究開発機構(T-CReDO)臨床研究地域イノベーション学(JA寄附講座)
All Rights Reserved.

ページトップ